Former Amryt Pharma leadership team to join Poolbeg

Three members of Irish-based Amryt Pharma’s former leadership team are set to assume “pivotal roles” at London-headquartered pharma and biotech firm Poolbeg Pharma.

David Allmond, John McEvoy and Laura Maher will join the company in the coming months.

Allmond will become chief business officer of Poolbeg, the same role he held at Amryt, from 1 December, while former Amryt global general council McEvoy will join as chief legal counsel and senior vice president on 1 January.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Poolbeg Pharma

More articles like this

Poolbeg Pharma’s Cathal Friel assumes role of Executive Chairman

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced a change of Board role and the Remuneration Committee’s approval of

What will cancer therapy look like in 2034?

Drugs like PARP inhibitors and chimeric antigen receptor (CAR) therapies, and advancements in artificial intelligence in drug discovery, have spurred hope for improved cancer care in the past year. Rigorous research has paved the way for a

Reducing cancer immunotherapy-induced CRS

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.